The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
The following is a summary of “Long-term effectiveness of aripiprazole once monthly on functioning and quality of life in schizophrenia: results of year 2 of the ReLiAM study,” published in the ...
AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...
A multitude of genes have been linked to the development of Alzheimer's disease. Specifically how those genes might influence ...
Verywell Health on MSN17h
Zepbound Cuts the Risk of Progressing to Diabetes by 94%, Eli Lilly Data ShowsEli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...
Objective Treatment compliance among psychiatric patients is related to disease outcomes. How to assess patient compliance remains a concern. Here, we established a predictive model for medication ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback